Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2025-12-26 @ 1:22 AM
Study NCT ID:
NCT07299994
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-23
First Post:
2025-12-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D020521', 'term': 'Stroke'}, {'id': 'D000083242', 'term': 'Ischemic Stroke'}], 'ancestors': [{'id': 'D002561', 'term': 'Cerebrovascular Disorders'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2025-04-22', 'size': 183266, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2025-12-04T11:04', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'RETROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 462}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2026-01-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2026-04-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-10', 'studyFirstSubmitDate': '2025-12-10', 'studyFirstSubmitQcDate': '2025-12-10', 'lastUpdatePostDateStruct': {'date': '2025-12-23', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-12-23', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2026-04-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Favorable outcome (mRS 0-1) at three months.', 'timeFrame': 'Three months after acute ischemic stroke treatment', 'description': 'Modified Rankin Scale (mRS) score at three months, with a favorable outcome defined as mRS 0-1 at three months.'}, {'measure': 'Early neurological deterioration within 24-48 hours after symptom onset', 'timeFrame': 'within 24-48 hours after acute ischemic stroke onset', 'description': 'Early neurological deterioration (END), defined as a worsening of the NIHSS score by ≥4 points within 24-48 hours after symptom onset.'}, {'measure': 'Occurrence of symptomatic intracerebral hemorrhage.', 'timeFrame': 'within three months after acute ischemic stroke treatment.', 'description': 'Occurrence of symptomatic intracerebral hemorrhage within three months after acute ischemic stroke treatment.'}], 'secondaryOutcomes': [{'measure': 'Good functional outcome (mRS 0-2)', 'timeFrame': 'three months after acute ischemic stroke treatment.', 'description': 'Modified Rankin Scale (mRS) score at three months, with a good outcome defined as mRS 0-2 at three months.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Acute ischemic Stroke', 'Branch Atheromatous Disease', 'Thrombolysis', 'DAPT', 'SAPT'], 'conditions': ['Stroke', 'Thrombolysis', 'DAPT(Dual Antiplatelet Therapy)', 'SAPT(Single Antiplatelet Therapy)', 'Acute Ischemic Stroke']}, 'referencesModule': {'references': [{'pmid': '32219364', 'type': 'BACKGROUND', 'citation': 'Naimi AI, Whitcomb BW. Estimating Risk Ratios and Risk Differences Using Regression. Am J Epidemiol. 2020 Jun 1;189(6):508-510. doi: 10.1093/aje/kwaa044. No abstract available.'}, {'pmid': '30907934', 'type': 'BACKGROUND', 'citation': 'Barow E, Boutitie F, Cheng B, Cho TH, Ebinger M, Endres M, Fiebach JB, Fiehler J, Ford I, Galinovic I, Nickel A, Puig J, Roy P, Wouters A, Magnus T, Thijs V, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Simonsen CZ, Gerloff C, Thomalla G; WAKE-UP Investigators. Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial. JAMA Neurol. 2019 Jun 1;76(6):641-649. doi: 10.1001/jamaneurol.2019.0351.'}, {'pmid': '34784740', 'type': 'BACKGROUND', 'citation': 'Xu J, Xu X, Wang H, He L, Liu Q, Du Y, Wang J. Dual Antiplatelet Therapy Plus Argatroban Prevents Early Neurological Deterioration in Branch Atherosclerosis Disease. Stroke. 2022 Jan;53(1):e19-e20. doi: 10.1161/STROKEAHA.121.036356. Epub 2021 Nov 17.'}, {'pmid': '32459110', 'type': 'BACKGROUND', 'citation': 'Liu B, Zhang H, Wang R, Qu H, Sun Y, Zhang W, Zhang S. Early administration of tirofiban after urokinase-mediated intravenous thrombolysis reduces early neurological deterioration in patients with branch atheromatous disease. J Int Med Res. 2020 May;48(5):300060520926298. doi: 10.1177/0300060520926298.'}, {'pmid': '32733357', 'type': 'BACKGROUND', 'citation': 'Wu X, Liu Y, Nie C, Kang Z, Wang Q, Sun D, Li H, Liu Y, Mei B. Efficacy and Safety of Intravenous Thrombolysis on Acute Branch Atheromatous Disease: A Retrospective Case-Control Study. Front Neurol. 2020 Jul 7;11:581. doi: 10.3389/fneur.2020.00581. eCollection 2020.'}, {'pmid': '39217764', 'type': 'BACKGROUND', 'citation': 'Kobayashi Y, Kondo Y, Yamamoto K, Hirayama S, Kuasano Y, Tazawa KI, Shimizu Y, Sato A, Sekijima Y. Tissue plasminogen activator for acute branch atheromatous disease exhibits transient improvement and worsening. J Neurol Sci. 2024 Oct 15;465:123201. doi: 10.1016/j.jns.2024.123201. Epub 2024 Aug 30.'}, {'pmid': '21402390', 'type': 'BACKGROUND', 'citation': 'Yamamoto Y, Ohara T, Hamanaka M, Hosomi A, Tamura A, Akiguchi I. Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits. J Neurol Sci. 2011 May 15;304(1-2):78-82. doi: 10.1016/j.jns.2011.02.006. Epub 2011 Mar 13.'}, {'pmid': '26032577', 'type': 'BACKGROUND', 'citation': 'Duan Z, Fu C, Chen B, Xu G, Tao L, Tang T, Hou H, Fu X, Yang M, Liu Z, Zhang X. Lesion patterns of single small subcortical infarct and its association with early neurological deterioration. Neurol Sci. 2015 Oct;36(10):1851-7. doi: 10.1007/s10072-015-2267-1. Epub 2015 Jun 2.'}, {'pmid': '27452127', 'type': 'BACKGROUND', 'citation': 'Park MG, Oh EH, Kim BK, Park KP. Intravenous tissue plasminogen activator in acute branch atheromatous disease: Does it prevent early neurological deterioration? J Clin Neurosci. 2016 Nov;33:194-197. doi: 10.1016/j.jocn.2016.04.011. Epub 2016 Jul 21.'}, {'pmid': '22133744', 'type': 'BACKGROUND', 'citation': 'Nakase T, Yoshioka S, Sasaki M, Suzuki A. Clinical evaluation of lacunar infarction and branch atheromatous disease. J Stroke Cerebrovasc Dis. 2013 May;22(4):406-12. doi: 10.1016/j.jstrokecerebrovasdis.2011.10.005. Epub 2011 Nov 30.'}, {'pmid': '31132967', 'type': 'BACKGROUND', 'citation': 'Uchiyama S, Toyoda K, Kitagawa K, Okada Y, Ameriso S, Mundl H, Berkowitz S, Yamada T, Liu YY, Hart RG; NAVIGATE ESUS Investigators. Branch atheromatous disease diagnosed as embolic stroke of undetermined source: A sub-analysis of NAVIGATE ESUS. Int J Stroke. 2019 Dec;14(9):915-922. doi: 10.1177/1747493019852177. Epub 2019 May 27.'}, {'pmid': '7678184', 'type': 'BACKGROUND', 'citation': 'Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993 Jan;24(1):35-41. doi: 10.1161/01.str.24.1.35.'}, {'pmid': '30356780', 'type': 'BACKGROUND', 'citation': 'Zhou L, Yao M, Peng B, Zhu Y, Ni J, Cui L. Atherosclerosis Might Be Responsible for Branch Artery Disease: Evidence From White Matter Hyperintensity Burden in Acute Isolated Pontine Infarction. Front Neurol. 2018 Oct 9;9:840. doi: 10.3389/fneur.2018.00840. eCollection 2018.'}, {'pmid': '21277587', 'type': 'BACKGROUND', 'citation': 'Kwan MW, Mak W, Cheung RT, Ho SL. Ischemic stroke related to intracranial branch atheromatous disease and comparison with large and small artery diseases. J Neurol Sci. 2011 Apr 15;303(1-2):80-4. doi: 10.1016/j.jns.2011.01.008. Epub 2011 Feb 1.'}, {'pmid': '26671513', 'type': 'BACKGROUND', 'citation': 'Petrone L, Nannoni S, Del Bene A, Palumbo V, Inzitari D. Branch Atheromatous Disease: A Clinically Meaningful, Yet Unproven Concept. Cerebrovasc Dis. 2016;41(1-2):87-95. doi: 10.1159/000442577. Epub 2015 Dec 16.'}, {'pmid': '2671793', 'type': 'BACKGROUND', 'citation': 'Caplan LR. Intracranial branch atheromatous disease: a neglected, understudied, and underused concept. Neurology. 1989 Sep;39(9):1246-50. doi: 10.1212/wnl.39.9.1246. No abstract available.'}]}, 'descriptionModule': {'briefSummary': 'Rationale and Relevance:\n\nBranch Atheromatous Disease (BAD) describes an atherosclerotic occlusion of one of the deep penetrating cerebral arteries, including the lenticulostriate artery (LSA), paramedian pontine artery (PPA), and anterior choroidal artery (ACHA). BAD is frequently associated with early neurological deterioration (END), particularly progressive motor deficits that contribute to increased disability. Despite its clinical relevance, BAD remains underrepresented in major radiomorphological classification systems such as TOAST, which has led to limited evidence and unclear treatment strategies. Previous studies suggest that the efficacy of intravenous thrombolysis (IVT) may be reduced in BAD compared to other stroke etiologies.\n\nObjectives:\n\nThe primary objective of this study is to evaluate the efficacy and safety of IVT compared with single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT) in patients with BAD-related stroke. A secondary objective is to examine the impact of acute-phase blood pressure fluctuations on END and functional neurological outcomes.\n\nDesign and Methods:\n\nThis international multicenter study will be conducted retrospectively according to the STROBE guidelines. Eligible patients include those with BAD-related stroke treated at one of the participating centers between 2010 and 2025. Inclusion criteria comprise characteristic diffusion-weighted MRI patterns in predefined vascular territories (LSA, PPA, ACHA) and a symptom onset ≤24 hours before admission. Patients with typical lacunar infarcts or with other identified stroke etiologies will be excluded.\n\nEndpoints:\n\nPrimary endpoints include functional outcome at three months, defined as a favorable outcome with a modified Rankin Scale score of 0-1; occurrence of END, defined as a ≥4-point worsening on the NIHSS within 24-48 hours; and symptomatic intracerebral hemorrhage. Collected data include clinical, imaging, and therapeutic variables, as well as blood pressure trajectories and pre-stroke treatments (as detailed in the study protocol).\n\nStatistical Analysis:\n\nAnalyses will be performed using SPSS and R. Descriptive statistics, univariate analyses, and multivariable models (IPTW and Poisson regression) will be applied. Results will be reported as adjusted relative risks with 95% confidence intervals.\n\nSignificance:\n\nThis study will provide the first comprehensive evaluation of IVT versus SAPT/DAPT in BAD-related stroke, and will investigate the clinical impact of blood pressure changes in this specific stroke subtype. The findings aim to support evidence-based treatment recommendations for a currently underrecognized and poorly understood stroke etiology.', 'detailedDescription': 'Background Intracranial branch atheromatous disease (BAD) describes an occlusion of deep penetrating intracranial arteries, leading to subcortical infarction. Perforating arteries include the lenticulostriate artery (LSA), paramedian pontine artery (PPA), anterior choroidal artery (ACHA), thalamoperforating artery, and Heubner\'s artery. This study focuses on BAD affecting the ACHA, LSA, and PPA.\n\nIn contrast to lacunar ischemia, which is caused by hypertensive lipohyalinotic degeneration of the distal segment of a perforating artery with a diameter ≤200 µm, BAD involves larger vessels (700-800 µm) affected by atherosclerosis of the parent artery. BAD has not been classified as a major cause of cerebral infarction by the National Institute of Neurological Disorders and Stroke (NINDS) or the Trial of Org 10172 in Acute Stroke Treatment (TOAST), which has contributed to a rather scarce data regarding clinical trajectories of this particular stroke etiology. According to TOAST criteria, BAD-related strokes are often categorized under small vessel occlusion or classified as an undetermined cause. Due to their vessel size, high pressure and flow, these arteries are more susceptible to endothelial damage and atherosclerosis, leading to fluctuating symptoms. At admission, BAD often presents similarly to lacunar ischemia. But in comparison, a main clinical characteristic of BAD is the frequent occurrence of early neurological deterioration (END), often manifesting as progressive motor deficits, which contribute to poorer outcomes and increased disability. Consequently, BAD has been recognized as a major vascular mechanism of progressive motor deficits in penetrating artery infarcts. Because of its unique pathophysiology and clinical progression, finding effective treatment strategies remains difficult. Intravenous thrombolysis (IVT) appears to be less effective for BAD compared to other etiologies of acute ischemic stroke. Previous studies have explored various treatment strategies, including dual antiplatelet therapy, tirofiban, and anticoagulation therapy, but results have been inconsistent. This study will assess the efficacy and safety of IVT versus antiplatelet therapy in BAD-related stroke. Furthermore, we will examine the impact of blood pressure on END and functional outcomes.\n\nAims The primary aim of this study is to assess the efficacy and safety of IVT compared to single (SAPT) or dual antiplatelet therapy (DAPT) in patients with BAD-related stroke. Secondary aim is to explore the impact of blood pressure fluctuations on END and functional outcomes and its potential interactions with acute therapies.\n\nMethods This study is an international multicenter observational study recruiting patients with BAD-related stroke in the acute phase on the stroke unit up to 24 hours before admission. As of March 26, 2025, this study has recruited six institutions, led by Department of Neurology, St. John\'s Hospital, Vienna, Austria and sponsored by Sigmund Freud University Vienna, Austria.\n\nStudy Population All patients with a BAD-related stroke, aged over 18 years, with symptom onset no more than 24 hours before admission, who were treated in one of the stroke units of the participating institutions between 01.01.2010 and 28.02.2025, will be included based on the following inclusion criteria. All enrolled patients must have undergone a cerebral MRI for inclusion.\n\nInclusion criteria\n\n1. DWI lesion: single isolated deep subcortical stroke AND\n2. The affected vessel involves the LSA, PPA, or ACHA, and the infarct lesion on DWI conforms to one of the following characteristics (A, B, OR C):\n\nA. LSA: "Comma-like" infarct lesions with "fan-shaped" extension from bottom to top in the coronary position OR ≥ 3 layers (layer thickness 5 mm) on axial DWI.\n\nB. PPA: Infarct lesion extending from the deep pons to the ventral pons on axial DWI.\n\nC. ACHA: Infarct within the anterior choroidal artery territory. Exclusion criteria\n\n1. Typical recent small subcortical infarction (RSSI) (oval, \\<20mm in all axes).\n2. ≥ 50% stenosis on the parent artery (i.e., BA, MCA, or ICA)\n3. Stroke due to other clearly identified causes or possible cardioembolic etiology.\n\nEndpoints\n\nThe primary endpoints of this study include:\n\n1. Modified Rankin Scale (mRS) score at three months, with a favorable outcome defined as mRS 0-1 at three months.\n2. Early neurological deterioration (END), defined as a worsening of the NIHSS score by ≥4 points within 24-48 hours after symptom onset.\n3. Occurrence of symptomatic intracerebral hemorrhage.\n\nInterventions Intravenous thrombolysis (IVT), single antiplatelet therapy (SAPT), dual antiplatelet therapy (DAPT)\n\nHypothesis\n\n1. H0. Patients with BAD related stroke treated using IVT will not achieve better functional outcome as compared to those treated with SAPT.\n\n H1. Patients with BAD related stroke treated using IVT will achieve better functional outcome as compared to those treated with SAPT.\n2. H0. Patients with BAD related stroke treated using IVT will not achieve better functional outcome as compared to those treated with DAPT.\n\n H1. Patients with BAD related stroke treated using IVT will achieve better functional outcome as compared to those treated with DAPT.\n3. H3. Patients with BAD-related stroke experiencing blood pressure drop \\>=30 mmHg in the first 24 hours after admission will not experience worse functional outcome as compared to those without blood pressure drop. Interaction with IVT will be significant.\n\nH3. Patients with BAD-related stroke experiencing blood pressure drop \\>=30 mmHg in the first 24 hours after admission will experience worse functional outcome as compared to those without blood pressure drop. Interaction with IVT will be significant.\n\nInformed consent Due to the retrospective nature of the study and the use of anonymized data, obtaining patient informed consent is not necessary.\n\nStudy sites Institutions participating in this study, with a full list of institutions provided under collaborating institutions. The leading institution is the Department of Neurology, St. John\'s Hospital, Vienna, Austria.\n\nStudy design The study will be conducted as an international multicenter retrospective observational study according to the STROBE guideline.\n\nSample size Although the study is retrospective, a sample size calculation was conducted. Based on outcome data from lacunar stroke patients, 59% of patients treated with IVT achieved a favorable outcome (mRS 0 - 1 at 3 months). Assuming an odds ratio (OR) of 1.67 in favor of IVT, this corresponds to an estimated 46% rate of favorable functional outcome in the control group. Using a two-sided alpha of 0.05 and a power of 80%, the calculated total sample size is 462 patients, with 231 in each group. The calculation was performed using G\\*Power (version 3.1.9.7, Düsseldorf, Germany).\n\nCollected data See study protocol\n\nData management Collected data will be entered into an electronic database at the primary study site. All data will be fully anonymized and only shared in this form with researchers. Therefore, a data monitoring committee will not be required. All datasets will be exclusively used for this study, and no third party will be granted access at any time.\n\nStatistics The statistical analysis will be conducted using SPSS version 29.0.1.0 (IBM Corp., Armonk, NY, USA) and R version 4.4.2 (R Foundation for Statistical Computing, Vienna, Austria). Continuous variables will be presented as mean ± standard deviation (SD) or median with interquartile range (IQR), depending on their distribution. Categorical variables will be expressed as frequencies (n) and percentages (%). This includes variables such as baseline characteristics, medical history, and treatment modalities. For the analysis of statistical significance in outcome measures, Pearson\'s χ² test or Fisher\'s exact test will be applied for categorical data, while Wilcoxon rank-sum tests or t-tests will be used for continuous variables, as appropriate. Statistical uncertainty will be reported using 95% confidence intervals (CI). To evaluate the association between three-month mRS and clinical or therapeutic predictors, IPTW and Poisson regression models will be utilized. The results of the Poisson regression analysis will be reported as adjusted relative risks (RR) with corresponding 95% CI. A favorable functional outcome is defined as mRS ≤1 at three months post-stroke. Statistical significance will be set at p\\<0.05.\n\nEthical considerations This study will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines throughout the whole research process. Approval from the ethics committee will be obtained prior to data collection. As this is a retrospective, non-interventional study, there is no additional physical risk for patients. Data collection is exclusively based on previously recorded medical records. The primary ethical concern in this study relates to data transfer between institutions. To minimize this risk, only fully anonymized data will be shared with researchers. All collected data will be used solely for scientific research purposes, and no personal information will be disclosed or made accessible to third parties.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'All patients with a BAD-related stroke, aged over 18 years, with symptom onset no more than 24 hours before admission, who were treated in one of the stroke units of the participating institutions.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* aged over 18 years, with acute ischemic stroke and symptom onset no more than 24 hours before admission, who were treated in one of the stroke units of the participating institutions.\n* All enrolled patients must have undergone a cerebral MRI for inclusion:\n\n 1. DWI lesion: single isolated deep subcortical stroke AND\n 2. The affected vessel involves the LSA, PPA, or ACHA, and the infarct lesion on DWI conforms to one of the following characteristics (A, B, OR C):\n\nA. LSA: "Comma-like" infarct lesions with "fan-shaped" extension from bottom to top in the coronary position OR ≥ 3 layers (layer thickness 5 mm) on axial DWI.\n\nB. PPA: Infarct lesion extending from the deep pons to the ventral pons on axial DWI.\n\nC. ACHA: Infarct within the anterior choroidal artery territory.\n\nExclusion Criteria:\n\n* Typical recent small subcortical infarction (RSSI) (oval, \\<20mm in all axes)\n* ≥ 50% stenosis on the parent artery (i.e., BA, MCA, or ICA)\n* Stroke due to other clearly identified causes or possible cardioembolic etiology.'}, 'identificationModule': {'nctId': 'NCT07299994', 'briefTitle': 'Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease', 'organization': {'class': 'OTHER', 'fullName': 'Sigmund Freud PrivatUniversitat'}, 'officialTitle': 'Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease - a Retrospective Data Analysis', 'orgStudyIdInfo': {'id': '17823177'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'IVT group', 'description': 'Patients who received intravenous thrombolysis as part of acute stroke treatment, if eligible.'}, {'label': 'Antiplatelet group', 'description': 'Patients who received SAPT or DAPT as part of acute stroke treatment.'}]}, 'contactsLocationsModule': {'locations': [{'zip': '1020', 'city': 'Vienna', 'country': 'Austria', 'contacts': [{'name': 'Julian Frederic Hotz, DDr.', 'role': 'CONTACT', 'email': 'julian.hotz@meduniwien.ac.at', 'phone': '+43 1 211210'}, {'name': 'Marek Sykora, Prof. Dr.', 'role': 'CONTACT', 'email': 'marek.sykora@bbwien.at', 'phone': '+43 1 211210'}], 'facility': "Department of Neurology, St. John's Hospital, Vienna, Austria", 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'zip': '1090', 'city': 'Vienna', 'country': 'Austria', 'contacts': [{'name': 'Stefan Greisenegger, Prof. Dr.', 'role': 'CONTACT', 'email': 'stefan.greisenegger@meduniwien.ac.at', 'phone': '+43 1 404000'}], 'facility': 'Department of Neurology, Medical University of Vienna', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'zip': '12200', 'city': 'Berlin', 'country': 'Germany', 'contacts': [{'name': 'Christian Nolte, Prof. Dr.', 'role': 'CONTACT', 'email': 'christian.nolte@charite.de', 'phone': '+49 30 450 560 676'}], 'facility': 'Department of Neurology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '69120', 'city': 'Heidelberg', 'country': 'Germany', 'contacts': [{'name': 'Jan Purrucker, Prof. Dr.', 'role': 'CONTACT', 'email': 'jan.purrucker@med.uni-heidelberg.de', 'phone': '00496221560'}], 'facility': 'Department of Neurology, Heidelberg University Hospital', 'geoPoint': {'lat': 49.40768, 'lon': 8.69079}}, {'zip': '72076', 'city': 'Tübingen', 'country': 'Germany', 'contacts': [{'name': 'Sven Poli, Prof. Dr.', 'role': 'CONTACT', 'email': 'sven.poli@uni-tuebingen.de', 'phone': '00497071290'}], 'facility': 'Department of Neurology & Stroke, University of Tübingen', 'geoPoint': {'lat': 48.52266, 'lon': 9.05222}}, {'zip': '3010', 'city': 'Bern', 'country': 'Switzerland', 'contacts': [{'name': 'Julian Frederic Hotz, DDr.', 'role': 'CONTACT', 'email': 'julian.hotz@insel.ch', 'phone': '0041316320648'}], 'facility': 'Department of Neurology, Universityhospital of Bern', 'geoPoint': {'lat': 46.94809, 'lon': 7.44744}}, {'zip': '1005', 'city': 'Lausanne', 'country': 'Switzerland', 'contacts': [{'name': 'Patrik Michel, Prof. Dr.', 'role': 'CONTACT', 'email': 'patrik.michel@chuv.ch', 'phone': '+41 21 314 11 11'}, {'name': 'Davide Strambo, PD Dr.', 'role': 'CONTACT', 'email': 'davide.strambo@chuv.ch', 'phone': '+41 21 314 11 11'}], 'facility': 'Stroke Center, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne', 'geoPoint': {'lat': 46.516, 'lon': 6.63282}}], 'centralContacts': [{'name': 'Julian Frederic Hotz, DDr.', 'role': 'CONTACT', 'email': 'julian.hotz@meduniwien.ac.at', 'phone': '+43 1 211210'}, {'name': 'Marek Sykora, Prof. Dr.', 'role': 'CONTACT', 'email': 'marek.sykora@bbwien.at', 'phone': '+43 1 211210'}], 'overallOfficials': [{'name': 'Julian Frederic Hotz, DDr.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "1. Department of Neurology, St. John's Hospital, Vienna, Austria, 2. Department of Neurology, University Hospital, Bern, Switzerland, 3. Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna"}, {'name': 'Marek Sykora, Prof. Dr.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "1. Sigmund Freud University Vienna, Austria, 2. Department of Neurology, St. John's Hospital, Vienna, Austria"}]}, 'ipdSharingStatementModule': {'infoTypes': ['STUDY_PROTOCOL', 'SAP'], 'ipdSharing': 'YES', 'description': 'Individual participant data that underlie the results after deidentification', 'accessCriteria': 'Data that support the findings of this study will available from the corresponding author after academic boards review and upon reasonable request'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Sigmund Freud PrivatUniversitat', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}